Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 4Breast Neoplasms 3Stomach Neoplasms 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Advanced Breast Cancer 1

Interventions

Psychiatric Rehabilitation 8Magnetic Resonance Spectroscopy 7Gemcitabine 7Capecitabine 7pembrolizumab 6Early Intervention, Educational 6Drug Therapy 6Cyclophosphamide 6Methods 5Therapeutics 4Specimen Handling 4Mental Status and Dementia Tests 4Docetaxel 4veliparib 3selpercatinib 3sargramostim 3palbociclib 3cediranib 3Trastuzumab 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Paclitaxel 3Oxaliplatin 3Irinotecan 3Fluorodeoxyglucose F18 3Counseling 3Cisplatin 3Carboplatin 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × ceralasertib × Breast × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡